

1 **Prevalence of and risk factors for high-risk HPV and cervical cytological** 2 **abnormalities in women living with HIV in Bali, Indonesia**

3

4 I Ketut Agus Somia¹, Made Lady Adelaida Purwanta², Ni Wayan Winarti³, Ida Bagus Nyoman
5 Putra Dwija⁴, Desak Made Putri Pidari⁵, A.A.S. Sawitri⁶, Anak Agung Ayu Yuli Gayatri⁷, I
6 Nyoman Gede Budiana⁸, Komang Januartha Putra Pinatih⁹, Ketut Tuti Parwati Merati¹⁰

7 ^{1,3,7,8} Prof dr IGNG Ngoerah Hospital – Faculty of Medicine, Udayana University Denpasar Bali

8 ^{2,4,6,9,10} Faculty of Medicine, Udayana University Denpasar Bali

9 ⁵ Kerti Praja HIV Foundation Clinic Denpasar Bali

10 *Corresponding author: I Ketut Agus Somia; Department of Internal Medicine, Tropical and
11 Infectious Disease Division, Udayana University/Prof. dr. I.G.N.G Ngoerah General Hospital,
12 Denpasar, Bali, Indonesia; email: agus_somia@yahoo.co.id

13

Abstract

14 **Background:** Women living with HIV face a higher risk of developing cervical cancer compared
15 to those without HIV. However, comprehensive cervical cancer screening programs for this
16 population are still lacking in Indonesia. This has resulted in many cases of late-stage cervical
17 cancer being diagnosed, especially in Bali, which has experienced an increase in cases of HIV and
18 cervical cancer. This study aimed to determine the prevalence of and risk factors for cervical
19 cytological abnormalities in women living with HIV in Bali and to explore their relationship with
20 high-risk HPV (HR-HPV) types.

21 **Methods:** This is a cross-sectional study with eligible participants recruited from outpatient HIV
22 clinics in Bali. Between July to December 2023, participants were interviewed to collect
23 demographic and historical medical information, followed by physical examination including
24 collection of cervical swabs and blood samples. Pap smear sampling and swab collection using
25 ThinPrep for cytology. HPV DNA was then identified by PCR and genotyped for HR-HPV
26 16,18,31,33,35,39,45,51,52,56,58,59,66,68. Blood samples were analyzed for CD4 and CD8 cell
27 counts.

28 **Results:** A total of 245 women with HIV at median age of 38 years old (24-50 years) and with
29 median time of ARV therapy of 7 years (0-18 years) were enrolled. Only 239 participants were
30 included in the analysis for their valid initial results. Overall, 26 (10.87%) of samples showed
31 abnormal cytology including 6 (2.5%) ASC-H, 9 (3.8%) ASC-US, 4 (1.7%) H-SIL and 7 (2.9%)
32 L-SIL. Of the 58 (24%) that tested positive for HPV DNA, 18 (31%) samples had abnormal
33 cytology. HPV 18 was the most common genotype detected (n=16 or 28%). Bivariate analysis
34 revealed a significant association between positive HPV DNA and abnormal cytology, with those
35 testing HPV-positive having seven times higher risk of ASC-US or greater
36 (PR=7.022;95%CI=3.223-15.295). Multivariate regression identified having HPV 18 infection as

37 an independent risk factor for abnormal cytology (ExpB=9.029;p=0.007), and a history of Pap
38 smear screening associated with reduced risk of HR-HPV infection (ExpB=0.358;p=0.013).

39 **Conclusion:** In our study, 10.87% of women living with HIV had abnormal cytology and 24%
40 had positive HPV DNA tests. HPV 18 was associated with a greater risk of abnormal cytology
41 compared to other high-risk HPV strains, but our sample size was small. History of pap smear was
42 also shown to decrease the risk of HR-HPV infection. The results underscore the need for increased
43 vaccination of younger women and screening of all women living with HIV in Indonesia in order
44 to improve their cervical health outcomes.

45

46 **Keywords:** High-risk HPV, cervical abnormalities, cervical cytological abnormalities, HIV, risk
47 factors

48

49 **Introduction**

50 Cervical cancer is one of the most frequently detected cancers in women living with HIV
51 and is classified as an AIDS-defining illness. From the meta-analysis of 24 studies shows that
52 women living with HIV have six times higher risk of developing cervical cancer compared to those
53 without HIV.(1) Globally, an estimated 6% of new cervical cancer cases in 2018 were diagnosed
54 among women living with HIV and 5% of all cases were attributable to HIV infection.¹ IARC
55 2021 data shows that in Indonesia, 0.3% of cervical cancer cases were caused by co-infection with
56 HIV. Due to being immunocompromised, women living with HIV are more prone to high-risk
57 HPV strains that often cause cervical cancer, this could even result in the persistence of the HPV
58 infection.(2,3) This leads to the urgency in early detection and management of cervical cancer in
59 the population of women living with HIV.

60 Cervical cancer screening in HIV population is crucial to avoid further complication and
61 mortality. Screening is the main strategy to reduce cervical cancer incidence, by detecting pre-
62 cancerous lesions that can be treated before evolving to cancer. This, which is followed by
63 adequate management is one of two prevention tools recommended by WHO that are highly
64 effective. Based on CDC guidelines, for woman with newly diagnosed HIV-infection, the first
65 cervical cancer screening is recommended by the time of HIV diagnosis and repeated on 6 or 12
66 months after diagnosis.(4) Effectiveness of the disease's management is influenced by not only
67 the accuracy of the screening method but also by the coverage of the cervical cancer treatment.
68 However, in reality many countries have yet conducted established screening program for cervical
69 cancer in this specific population, especially those of developing countries.

70 Indonesia was still considered at a low rate of cervical cancer screening (12%) per 2020,
71 resulting in an emergency situation for cervical cancer until recently.(5) Many patients came to the
72 hospital with their end-stage cancer due to the late diagnosis. On the other hand, there has also
73 been increasing number of HIV cases. Based on the recapitulation data of the early detection of
74 cervical cancer in Indonesia 2016, the number of suspected cervical cancer in several provinces
75 such as Jakarta were 269 cases, Bali with 254 cases and Bangka Belitung with 227 cases. The
76 data showed that Bali was one of the areas with high cervical cancer rates in 2016. Furthermore,

77 this number increased in 2019 for Bali with the incidence of cervical cancer of 437 cases. On the
78 other hand, Bali was on the sixth position for the highest HIV cases in Indonesia with 28,376 cases
79 until June 2022 as stated by the Indonesian Ministry of Health June 2022.(6)However, there has
80 yet been any data on the number of cervical cancer in this HIV population.

81 A number of risk factors could also influence the risk of cervical cytological abnormalities
82 and cervical cancer in women living with HIV. Besides late screening, it was thought that late
83 ART initiation or at lower CD4 cell counts could increase the risk of developing cervical cancer.
84 ART are expected to decrease viral load and help improve CD4 cell counts, thus enhancing
85 clearance of HPV and reducing the incidence of cervical cytological abnormalities.(2) Therefore,
86 inequities in access to effective cervical cancer screening and treatment of precancerous cervical
87 lesions are likely to be the main driver of high invasive cervical cancer rates in women living with
88 HIV.

89 Due to the reasoning above, we would like to determine the prevalence and risk factors of
90 cervical cytological abnormalities in women living with HIV in Bali, Indonesia, as well as to find
91 its association with the high-risk HPV possible of cervical cancer. This study will provide not only
92 the actual data of the local population to define future action in eradicating cervical cancer, but
93 also directly provide benefit in the form of early detection for women living with HIV in Bali.

94 **Methods**

95 ***Study design and setting***

96 This research was an observational study with cross-sectional design carried out at Yayasan
97 Kerti Praja HIV foundation Denpasar Bali clinic 26th of July 2023 – 11th of December 2023. The
98 respondents were women living with HIV who had regular appointments at the HIV clinics in Bali.
99 All participants gave their consent by signing on a written informed consent. This study has been
100 granted an ethical statement from the Ethic Committee of Faculty of Medicine, Udayana
101 University with the number: 1661/UN14.2.2.VII.14/LT/2023.

102

103 **Patient selection and sampling**

104 We included all women living with HIV of age 18-50 years old that attended the clinics. The
105 inclusion criteria: 1) women living with HIV of age 18-50 years old; 2) Indonesian nationality; 3)
106 has had sexual intercourse and willing to give their informed consent and exclusion criteria: 1)
107 mentally unstable; 2) cervical cancer patients; 3) on menstruation during data collection; 4)
108 pregnant women; 5) history of previous pap smear and/or HPV testing in the last 6 months; 6) on
109 treatment of all types of pre-malignancy or malignancy and/or had hysterectomy.

110 Number of samples were calculated based on the sample size formula for cross-sectional
111 design of proportional outcome. With the level of acceptable error of 5% and the expected
112 proportion in population of 19.05%,(7) and at the 5% types I error rate, the minimum number of
113 samples required was 237. Potential candidates were approached with consecutive sampling.

114 We screened 300 eligible candidates of women living with HIV, where these women had no
115 certain symptoms, but rather concern regarding their predisposition to the disease. The screening
116 procedure was done in a similar way to one of the algorithms (Algorithm 3) in the WHO Guidelines

117 of Cervical Cancer Screening.(8) For research purpose, all participants in the study went through
118 cytology screening with ThinPrep pap smear and HPV DNA testing simultaneously. This was
119 done altogether to give a complete picture of all participants involved in this study as part of the
120 Indonesian ethnicity.

121

122 **Study procedures**

123 Blood samples were analyzed for CD4 and CD8 cell counts using the flow cytometry method using
124 FACSVia (R656874100022) / FASClyric tool (R659180000700)

125 ***Cytology identification***

126 Cytological tests were performed by liquid based preparation technique (ThinPrep, Hologic, Inc.,
127 USA). All specimens were taken using ThinPrep swab kit, processed with a ThinPrep machine,
128 stained with Papanicolaou stain, and assessed microscopically by a pathologist based on The
129 Bethesda System criteria.

130 ***PCR for HPV DNA and genotyping***

131 Vaginal swab samples were collected and inserted into ThinPrep cytology media (ThinPrep
132 PreservCyt Solution1 REF 70097-005—Hologic, Inc. Marlborough, MA, USA). Subsequently,
133 the fluid in the cytology tube was vortexed, and 1 ml of ThinPrep fluid was transferred to a
134 microcentrifuge tube. Centrifugation was performed at 12,000 RPM for 1 minute, and the pellet
135 was washed with distilled water. DNA extraction was carried out using the Zymo Quick-DNATM
136 Miniprep Plus Kit according to the manufacturer's instructions. The extracted DNA was then
137 stored at -20°C until use. Next, PCR was performed with a total volume of 10 µl, consisting of 10
138 nM forward and reverse primers, PCR mix, and distilled water. PCR was conducted in two stages;
139 the first stage used the MY09/11 universal primers, and positive samples were followed by type-
140 specific PCR using specific primers for HPV 16,18,31,33,35,39,45,51,52,58,59,66,68, and 69.
141 PCR was carried out on a Veriti™ machine (AB Biosystem) with a denaturation PCR program
142 of 95°C for 5 minutes, followed by 35 cycles of 95°C for 1 minute, 95°C for 20 seconds, 55°C for
143 45 seconds, 72°C for 60 seconds, and a final extension at 72°C for 7 minutes. PCR results were
144 visualized using 1.5% agarose gel with GelRed staining under UV light

145

146 **Statistics**


147 Initially, descriptive statistics were used to summarize the demographic and clinical
148 characteristics of the study population. The prevalence of cervical abnormalities and HPV
149 infection rates were calculated. Bivariate analysis was conducted to explore the association
150 between HPV DNA positivity and abnormal cytology results. The strength of this association was
151 quantified using odd ratio (ORs) with corresponding 95% confidence intervals (CIs). Multivariate
152 logistic regression analysis was then performed to identify independent risk factors for cervical
153 abnormalities, adjusting for potential confounders that had association in bivariate analysis of less
154 than 0.25. The significance of multivariate analysis was determined with a threshold of p-value
155 less than 0.05. We used SPSS version 29 to conduct the analysis.

156

157 Results

158 From the targeted population, we received a list of 300 potential candidates for screening.
159 After referred to the inclusion and exclusion criteria, we recruited 245 eligible participants, from
160 which 239 samples (97.6%) were successfully analyzed. We had to repeat sampling 10 cases due
161 to initial sampling inadequacy, attributed to challenging conditions such as difficult portio access
162 or the presence of inflammatory cells. The research team gave significant efforts to communicate
163 with participants requiring re-sampling, providing detailed explanations about the importance of
164 the repeat pap smear procedure and the potential health benefits. Out of these ten needed to repeat,
165 there were six samples excluded from the final analysis, two of these were due to suspected
166 cervical cancer, and the other four were due to logistical issues (two participants relocated and
167 could not return, and two declined to participate further despite multiple contact attempts, resulting
168 in lost to follow up). The team still provided results from the initial tests along with health education
169 and preventive advice concerning cervical cancer (see Figure 1).

170



171

172

Figure 1. Recruitment process during the study

173

174 Baseline characteristics of study participants

175 Based on Table 1, the characteristics of study participants were grouped based on the
176 presence or absence of cervical cytological abnormalities, categorized across various demographic
177 and behavioral factors. The findings indicated that divorced individuals represented 8.8% of those
178 with cytological abnormalities, while 91.3% did not have these conditions. Education levels
179 revealed a slightly higher incidence cytological abnormalities among those with higher education,
180 with those having completed high school or more showing a greater percentage compared to those
181 with less education. Employment status correlated with cytological abnormalities prevalence,
182 where 15.5% of unemployed participants had cytological abnormalities compared to 8.9% of
183 employed participants. The analysis also considered lifestyle factors such as alcohol consumption

184 and contraception use, noting that none of the alcohol consumers in the study had cytological
 185 abnormalities, and those using contraception exhibited a higher percentage of cytological
 186 abnormalities than those who did not. Sexual behavior was also a factor, with participants who had
 187 more sexual partners or an earlier sexual debut showing slightly higher percentages of cytological
 188 abnormalities. Additional factors like gravidity, hormonal medication use, and history of abortion
 189 were examined, each contributing to the understanding of how these characteristics were
 190 associated with the presence of ASC or cervical cytological abnormalities among the participants.

191 **Table 1.** Characteristics of samples based on with and without cervical cytological abnormalities
 192 (categorical variables)

Variables	With cytological abnormalities (n, %)	Without cytological abnormalities (n, %)	p-value	Odd ratio (95%CI)
Marital Status (n=239)				
Divorced	7 (8.8%)	73 (91.3%)	0.492	-
Married	18 (12.8%)	123 (87.2%)		
Single	1 (5.6%)	17 (94.4%)		
Education (n=239)				
<High School	8 (9.1%)	80 (90.9%)	0.498 ^a	-
≥High School	18 (11.9%)	133 (88.1%)		
Occupation				
Unemployed	11 (15.5%)	60 (84.5%)	0.136 ^a	0.535 (0.232-1.230)
Employed	15 (8.9%)	153 (91.1%)		
Alcohol (n=239)				
Yes	0 (0%)	1 (100.0%)	1.000 ^b	-
No	26 (10.9%)	212 (89.1%)		
Contraception (n=239)				
Yes	17 (14.5%)	100 (85.5%)	0.076 ^a	2.134 (0.911-5.002)
No	9 (7.4%)	113 (92.6%)		
Number of Sexual Partner (n=239)				
≥5	6 (8.5%)	65 (91.5%)	0.433 ^a	-
<5	20 (11.9%)	148 (88.1%)		
Sexual debut year (n=239)				
<21	17 (10.7%)	142 (89.3%)	0.896 ^a	-
≥21	9 (11.3%)	71 (88.8%)		
Viral load (n=182)				
Detected	5 (16.1%)	26 (83.9%)	0.329 ^a	-
Not detected	14 (9.3%)	137 (90.7%)		
HIV Duration (years) (n=239)				

≥5	15 (9.4%)	145 (90.6%)	0.288 ^a	-
<5	11 (13.9%)	68 (86.1%)		
ARV Treatment Duration (Years) (n=239)				
≤1	6 (15.0%)	34 (85.0%)	<u>0.242</u>	-
2-4	7 (15.9%)	37 (84.1%)		
≥5	13 (8.4%)	142 (91.6%)		
Smoking status (n=239)				
Yes	3 (9.7%)	28 (90.3%)	1.000 ^b	-
No	23 (11.1%)	185 (88.9%)		
HPV infection history (n=239)				
Yes	4 (18.2%)	18 (81.8%)	0.274 ^b	-
No	22 (10.1%)	195 (89.9%)		
Pap smear history (n=239)				
Yes	7 (5.6%)	119 (94.4%)	0.005 ^{***a}	0.291 (0.117-0.721)
No	19 (19.8%)	94 (83.2%)		
HPV Vaccine Status (n=239)				
No	26 (11.1%)	208 (88.9%)	1.000 ^b	-
Yes	0 (0%)	5 (100%)		
Gravidity (n=239)				
No gravidity	2 (7.7%)	24 (92.3%)		
≤2	12 (9.2%)	118 (90.8%)	0.420	-
>2	12 (14.5%)	71 (85.5%)		
Hormonal medication (n=239)				
Yes	1 (25%)	3 (75%)	0.371 ^b	-
No	25 (10.6)	210 (89.4%)		
Abortion (n=239)				
Yes	7 (8%)	81 (92%)	0.268 ^a	-
No	19 (12.6%)	132 (87.4%)		
History of STDs (n=239)				
Yes	4 (19%)	17 (81%)	0.260 ^b	-
No	22 (10.1%)	196 (89.9%)		
Menopause (n=239)				
Yes	1 (4%)	24 (96%)	0.328 ^b	-
No	25 (11.7%)	189 (88.3%)		
Universal HPV DNA results (n=239)				
HPV (+)	18 (31.0%)	40 (69.0%)	0.000 ^{a**}	9.731 (3.952-23.959)
HPV (-)	8 (4.4%)	173 (95.6%)		

193 ^aanalysed by chi-square test

194 ^banalysed by fisher's exact test

195

196 Based on Table 2, it was found that the average age of participants with cytological
 197 abnormalities was slightly younger at 35.5 years compared to 38 years for those without these
 198 conditions, although this difference was not statistically significant. Notably, the CD4 cell count
 199 showed a significant difference, with a median count of 415 cells/uL in those with Cytological
 200 abnormalities versus 556 cells/uL in those without, suggesting a lower immune status in the
 201 affected group. Similarly, the percentage of CD4 cells was significantly lower in participants with
 202 Cytological abnormalities, averaging 21.34%, compared to 26.62% in those without, further
 203 indicating compromised immune function in the former group. The CD8 cell count and percentage
 204 did not show significant differences. However, the CD4/CD8 ratio was significantly lower in
 205 participants with Cytological abnormalities, with a median of 0.43 compared to 0.63 in those
 206 without, underscoring a more pronounced immune system imbalance in those with cervical
 207 abnormalities.

208 **Table 2.** Characteristics of samples based on with and without cervical cytological abnormalities

Variables	With cytological abnormalities (mean±SD or median (min-max))	Without cytological abnormalities (mean±SD or median (min-max))	p-value (CI95%)
Age (years)	35.5 (27-47)	38 (24-50)	0.330 ^c
CD4# (sel/uL)	415 (65-1132)	556 (103-1680)	0.011* ^c
CD8# (sel/uL)	1009 (299-2268)	857 (277-1839)	0.398 ^c
CD4%	21.34±9.87	26.62±8.63	0.004** (1.6918-8.8726) ^d
CD8%	46.86 (18.42-68.18)	39.62 (20.28-74.31)	0.013* ^c
CD4/CD8 Ratio	0.43 (0.13-1.41)	0.63 (0.07-1.75)	0.005*** ^c

209 ^canalysed by mann-whitney test

210 ^danalysed by independent T-test

211 *p<0.05

212

213 Since there were eight non-typeable samples, we only included 231 samples to identify the
 214 risk factors of high-risk HPV infection in women living HIV. Based on Table 3, the characteristics
 215 of samples with and without high-risk HPV infection were analyzed. It was found that marital
 216 status varied, with divorced participants making up 22.1% of those with HPV and 77.9% of those
 217 without. Married participants constituted 20.3% of the HPV-positive group and 79.7% of the HPV-
 218 negative group, while single participants represented 31.3% of those with HPV and 68.8% without.
 219 Education levels also showed differences; those with less than high school education made up
 220 19.8% of the HPV-positive group and 80.2% of the HPV-negative group. Regarding contraception

221 use, 25.2% of those using contraception were HPV-positive compared to 74.8% who were
 222 negative. The number of sexual partners also correlated with HPV status; 27.3% of those with
 223 more than five partners were HPV-positive.

224

225 **Table 3.** Characteristics of samples with and without high-risk HPV infection

Variables	HPV (+) (n, %)	HPV (-) (n, %)	p-value	Odd ratio (95%CI)
<i>Marital Status (n=231)</i>				
Divorced	17 (22.1%)	60 (77.9%)	0.598	-
Married	28 (20.3%)	110 (79.7%)		
Single	5 (31.3%)	11 (68.8%)		
<i>Education (n=231)</i>				
<High School	17 (19.8%)	69 (80.2%)	0.594 ^a	-
≥High School	33 (22.8%)	112 (77.2%)		
<i>Occupation (n=231)</i>				
Unemployed	17 (23.9%)	54 (76.1%)	0.572 ^a	-
Employed	33 (20.6%)	127 (79.4%)		
<i>Alcohol (n=231)</i>				
Yes	1 (100%)	0 (0%)	<u>0.216^b</u>	4.694 (3.662-6.017)
No	49 (21.3%)	181 (78.7%)		
<i>Contraception (n=231)</i>				
Yes	28 (25.2%)	83 (74.8%)	<u>0.204^a</u>	1.376 (0.839-2.258)
No	22 (18.3%)	98 (81.7%)		
<i>Number of Sexual Partner (n=231)</i>				
≥5	18 (27.3%)	48 (72.7%)	<u>0.189^a</u>	1.406 (0.851-2.323)
<5	32 (19.4%)	133 (80.6%)		
<i>Sexual debut year (n=231)</i>				
<21	38 (24.7%)	116 (75.3%)	<u>0.114^a</u>	0.632 (0.351-1.138)
≥21	12 (15.6%)	65 (84.8%)		
<i>Viral load (n=176)</i>				
Detected	7 (23.3%)	23 (76.7%)	0.672 ^a	-
Not detected	29 (19.9%)	117 (80.1%)		
<i>HIV Duration (years) (n=231)</i>				
≥5	21 (13.6%)	133 (86.4%)	<u>0.000^{**a}</u>	0.362 (0.222-0.591)
<5	29 (37.7%)	48 (62.3%)		
<i>ARV Treatment Duration (Years) (n=231)</i>				
≤1	20 (52.6%)	18 (47.4%)	<u>0.000^{**}</u>	-

2-4	11 (25.6%)	32 (74.4%)		
≥5	19 (12.7%)	131 (87.3%)		
Smoking status (n=231)				
Yes	8 (26.7%)	22 (73.3%)	0.480 ^a	-
No	42 (20.9%)	159 (79.1%)		
HPV infection history (n=231)				
Yes	6 (27.3%)	16 (72.7%)	0.586 ^b	-
No	44 (21.1%)	165 (78.9%)		
Pap smear history (n=231)				
Yes	17 (14.2%)	103 (85.8%)	<u>0.004**a</u>	0.477 (0.282-0.806)
No	33 (29.7%)	78 (70.3%)		
HPV Vaccine Status (n=231)				
No	50 (22.1%)	176 (77.9%)	0.588 ^b	
Yes	0 (0%)	5 (100%)		
Gravidity (n=231)				
No gravidity	10 (40%)	15 (60%)	<u>0.060</u>	
≤2	25 (20%)	100 (80%)		
>2	15 (18.5%)	66 (81.5%)		
Hormonal medication (n=231)				
Yes	3 (75%)	1 (25%)	<u>0.033*b</u>	3.622 (1.948-6.737)
No	47 (20.7%)	180 (79.3%)		
Abortion (n=231)				
Yes	15 (17.4%)	71 (82.6%)	<u>0.232a</u>	0.723 (0.420-1.244)
No	35 (24.1%)	110 (75.9%)		
History of STDs (n=231)				
Yes	6 (28.6%)	15 (71.4%)	0.412 ^b	
No	44 (21%)	166 (79%)		
Menopause (n=231)				
Yes	4 (16%)	21 (84%)	0.468 ^b	
No	46 (22.3%)	160 (77.7%)		

226 ^aanalysed by chi-square test

227 ^banalysed by fisher's exact test

228

229 From the analysis presented in Table 4, key findings regarding the characteristics of samples
 230 with and without high-risk HPV infection were observed. The age of participants did not show a
 231 significant difference, with both HPV-positive and HPV-negative groups having a median age of
 232 38 years. However, there was a significant difference in CD4 cell counts; participants with HPV

233 had a median CD4 count of 407 cells/uL, while those without HPV had a higher median of 594
 234 cells/uL. This suggested a lower immune status in the HPV-positive group. Additionally, the
 235 percentage of CD4 cells was significantly lower in the HPV-positive participants, averaging 21%
 236 compared to 27.44% in the HPV-negative group. The CD8 cell counts were similar between the
 237 two groups, but the CD4/CD8 ratio was significantly lower in the HPV-positive group, with a
 238 median of 0.44 compared to 0.68 in the HPV-negative group, indicating a more pronounced
 239 immune system imbalance in those with high-risk HPV infection.

240 **Table 4.** Characteristics of samples with and without high-risk HPV infection

Variables	HPV (+) (mean±SD or median (min-max))	HPV (-) (mean±SD or median (min-max))	p-value (CI95%)
Age (years)	38 (24-48)	38 (24-50)	0.178 ^c
CD4# (sel/uL)	407 (65-1214)	594 (103-1680)	0.000 ^{**c}
CD8# (sel/uL)	881 (299-2268)	854 (277-1839)	0.602 ^c
CD4%	21±10.53	27.44±7.86	0.000 ^{**} (-9.6311-(-3.2436)) ^d
CD8%	45.72±12.08	39.16 (20.28-70.13)	0.002 ^{**c}
CD4/CD8 Ratio	0.44 (0.11-1.75)	0.68 (0.07-1.54)	0.000 ^{**c}

241 ^canalysed by mann-whitney test

242 ^danalysed by independent T-test

243 *p<0.05

244 **p<0.01

245

246 ***HPV genotyping and cytology results***

247 In the study, Table 5 and Table 6 provided insights into Pap smear and HPV genotyping
 248 results. The Pap smear results showed that 37.7% of the samples were normal, while various
 249 abnormalities were detected: 2.5% had Atypical Squamous Cells of High Grade (ASC-H), 3.8%
 250 had Atypical Squamous Cells of Undetermined Significance (ASC-US), 1.7% had High Grade
 251 Squamous Intraepithelial Lesion (H-SIL), and 2.9% had Low Grade Squamous Intraepithelial
 252 Lesion (L-SIL). The HPV genotyping revealed that HPV 18 was the most prevalent, found in
 253 56.2% of the samples with Cytological abnormalities, significantly higher than other types. HPV
 254 16, 51, and 52 were also detected but with lower frequencies. The results from these tables
 255 underscored the prevalence of high-risk HPV types among women with HIV and their association
 256 with various grades of cervical abnormalities.

257 **Table 5.** Cytological Abnormalities and HPV genotyping

Variables	Frequency (n=239)
-----------	-------------------

Cytological abnormalities	26 (10.87%)
Atypical squamous cells high grade (ASC-H)	6 (2.5%)
Atypical squamous cells of undetermined significance (ASC-US)	9 (3.8%)
High Grade Squamous Intraepithelial Lesion (H-SIL)	4 (1.7%)
Low Grade Squamous Intraepithelial Lesion (L-SIL)	7 (2.9%)
HPV DNA universal analysis	
Positive	58 (24.3%)
Negative	181 (75.7%)
HPV genotyping (n=58)	
Single genotyping	40 (69%)
Double genotyping	
16, 18	2 (3.4%)
16, 52	1 (1.7%)
18, 45	3 (5.2%)
18, 52	2 (3.4%)
51, 58	1 (1.7%)
56, 58	1 (1.7%)
Untypeable	8 (13.8%)
HPV genotypes (n=58)	
HPV 16	7 (12.1%)
HPV 18	16 (27.6%)
HPV 31	4 (6.9%)
HPV 33	1 (1.7%)
HPV 45	3 (5.2%)
HPV 51	2 (3.4%)
HPV 52	9 (15.5%)
HPV 56	9 (15.5%)
HPV 58	9 (15.5%)
HPV 35,39,59,66,68	0 (0%)

258

259 **Table 6.** Distribution of samples into cytology groups based on HPV genotypes (n=239)

HPV genotype	With Cytological abnormalities (n, %)	Without Cytological abnormalities (n, %)	p-value
HPV 16 (+)	3 (42.9%)	4 (57.1%)	
Other than HPV 16	15 (29.4%)	36 (70.6%)	0.000**
Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 18 (+)	9 (56.2%)	7 (43.8%)	
Other than HPV 18	9 (21.4%)	33 (78.6%)	0.000**

Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 31 (+)	2 (50.0%)	2 (50.0%)	
Other than HPV 31	16 (29.6%)	38 (70.4%)	0.000**
Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 33 (+)	0 (0.0%)	1 (100.0%)	
Other than HPV 33	18 (31.6%)	39 (68.4%)	-
Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 45 (+)	1 (33.3%)	2 (66.7%)	
Other than HPV 45	17 (30.9%)	38 (69.1%)	0.000**
Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 51 (+)	1 (50.0%)	1 (50.0%)	
Other than HPV 51	17 (30.4%)	39 (69.6%)	0.000**
Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 52 (+)	4 (44.4%)	5 (55.6%)	
Other than HPV 52	14 (28.6%)	35 (71.4%)	0.000**
Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 58 (+)	0 (0.0%)	9 (100.0%)	
Other than HPV 58	18 (36.7%)	31 (63.3%)	-
Negative for HPV	8 (4.4%)	173 (95.6%)	

260

261 **Multivariate analysis of cervical cytological abnormalities' risk factors**

262 Table 7 provided a multivariate analysis of the risk factors for cervical cytological
 263 abnormalities in women living with HIV. The analysis revealed that HPV 18 was a significant
 264 independent risk factor, with an exponent (B) of 9.029 and a p-value of 0.007, indicating a strong
 265 association between HPV 18 infection and the presence of cervical abnormalities. Other HPV
 266 types such as HPV 16, 31, 45, 51, and 52 were also analyzed, but they did not show significant
 267 associations as their p-values were higher, suggesting less impact on the risk of cervical cytological
 268 abnormalities. Additionally, a history of Pap smear screening showed a trend towards reducing the
 269 risk of cervical abnormalities, although it was not statistically significant with a p-value of 0.083.
 270 The analysis underscored the critical role of HPV 18 in contributing to cervical cytological
 271 abnormalities among women with HIV and highlighted the potential protective effect of regular
 272 Pap smear screenings.

273

274 **Table 7.** The effects of all the potential risk factors on the risk of cervical cytological abnormalities
 275 in women with HIV in this study (n= 239)

Covariates	Exponent (B)	P-value	95% CI
HPV DNA	2.800	0.177	0.629 – 12.45
HPV 16	1.99	0.492	0.280 – 14.155
HPV 18	9.029	0.007**	1.835 – 44.425
HPV 31	3.908	0.300	0.298 – 51.317

HPV 45	0.617	0.745	0.034 – 11.327
HPV 51	8.295	0.200	0.327 – 210.262
HPV 52	3.277	0.207	0.519 – 20.680
Papsmear history	0.374	0.083	0.123 – 1.138
ARV treatment duration (≤ 1 year)	0.388	0.212	0.088 – 1.718
Contraception history	2.710	0.065	0.940 – 7.809
Occupation (unemployed)	1.845	0.250	0.650 – 5.235
CD4:CD8 ratio	0.378	0.234	0.076 – 1.876

276

277 ***Multivariate analysis of high-risk HPV infection risk factors***

278 Table 8 presented a multivariate analysis of the risk factors for high-risk HPV infection in
 279 women living with HIV. The findings indicated that a history of contraception use was marginally
 280 significant as a risk factor, with an exponent (B) of 2.189 and a p-value of 0.053, suggesting a
 281 potential association with increased risk of HPV infection. The number of sexual partners and the
 282 age at sexual debut did not show significant associations with HPV infection, as indicated by their
 283 p-values. Notably, a history of Pap smear screening was significantly associated with a reduced
 284 risk of high-risk HPV infection, with an exponent (B) of 0.358 and a p-value of 0.013, highlighting
 285 the protective effect of regular screening. The duration of ARV treatment and other factors like
 286 gravidity, abortion, and hormonal treatment did not show significant associations with HPV risk.
 287 This analysis underscored the importance of Pap smear history in reducing the risk of HPV
 288 infection among women with HIV.

289

290 **Table 8.** The effects of all the potential risk factors on the risk of high-risk HPV infection in
 291 women with HIV in this study (n= 231)

Covariates	Exponent (B)	P-value	95% CI
Contraception history	2.189	0.053	0.989 – 4.845
Number of sexual partner (≥ 5 people)	1.368	0.463	0.592 – 3.161
Sexual debut year (≥ 21 years old)	0.573	0.218	0.236 – 1.390
HIV duration (≥ 5 years)	0.542	0.388	0.135 – 2.175
ARV treatment duration (≤ 1 year)	2.504	0.239	0.544 – 11.519
Pap smear History	0.358	0.013*	0.160 – 0.802
Gravidity (> 2 times)	0.481	0.239	0.142 – 1.628
Abortion	0.682	0.360	0.301 – 1.546
Hormonal treatment	8.319	0.106	0.637 – 108.736
Age	1.020	0.522	0.960 – 1.084
CD4:CD8	0.349	0.093	0.103 – 1.190

292

293 **Discussion**

294 *HR-HPV 18 as a risk factor of cervical abnormalities in women living with HIV*

295 Our study found that HR-HPV 18 as the only significant risk factor of cervical cytological
296 abnormalities, potential of cervical cancer. However, a meta-analysis 2021 represents a different
297 scenario where HPV 16 was identified as the most prevalent genotype, particularly in the regions
298 of India, Thailand, and China.(9) Another study of meta-analysis about HPV genotypes in Kenya
299 also showed that HPV 16 as the most common infection, with HPV 18 came second. HPV 16 was
300 consistently identified as the most prevalent genotype in women with abnormal cytology and ICC.
301 For instance, in women with abnormal cytology, HPV 16 was found to be present in 26% of cases,
302 and in women with ICC, its prevalence increased to 37%.(10) This indicates a clear escalation in
303 the prevalence of HPV 16 as the severity of cervical disease increases. Following HPV 16, HPV
304 18 is the second most common genotype in ICC cases, with a prevalence of 24%. This discrepancy
305 highlights the geographical and demographic variations in HPV genotype distribution, which is a
306 crucial factor in understanding the epidemiology of HPV and its associated risks for cervical
307 cancer.

308 HPV 18, along with HPV 16, belongs to the high-risk category of HPV genotypes that are
309 strongly associated with the development of cervical cancer. These genotypes are known for their
310 ability to integrate into the host cell DNA, disrupting normal cell functions and leading to the
311 progression of precancerous lesions to invasive cancer.(11) The variation in prevalence between
312 our findings and the previous studies could be attributed to differences in study populations,
313 methodologies, or regional public health practices such as the prevalence of vaccination and
314 screening. This underlines the importance of localized data to inform public health strategies
315 effectively. For regions where HPV 18 is more prevalent, targeted interventions to address this
316 specific risk factor are crucial.(10) This includes promoting HPV vaccination that covers HPV 18,
317 enhancing screening programs to detect and treat precancerous changes early, and educating the
318 public and healthcare providers about the risks associated with HPV 18.

319 *Pap smear as an effective preventive measure of cervical cancer*

320 The Pap smear is a critical preventive measure for cervical cancer, particularly significant
321 for HIV-seropositive women in developing countries. As a cytological-based test, the Pap smear
322 has been extensively utilized in developed countries for many years, demonstrating substantial
323 success in reducing both the incidence and mortality of cervical cancer.(12)

324 One of the primary benefits of the Pap smear is its ability to detect precancerous changes in
325 the cervix, known as cervical intraepithelial neoplasia (CIN), at an early stage. Early detection
326 allows for the effective treatment of these changes before they have the chance to progress to
327 cancer. Consequently, this early intervention significantly contributes to the reduction in mortality
328 associated with cervical cancer, as treatments tend to be more effective at earlier stages.(5,13)

329 Moreover, the Pap smear is a cost-effective procedure. It does not require highly specialized
330 equipment, which makes it a viable option for many healthcare settings, including those with
331 limited resources typical of developing countries. The success of the Pap smear in developed
332

333 countries highlights its potential effectiveness when implemented with regular screenings and
334 proper follow-up care.(5)

335 Despite its benefits, the implementation of the Pap smear in developing countries faces
336 several challenges. These include a lack of proper infrastructure, insufficient qualified personnel,
337 and limited resources, which can impede the utilization and effectiveness of the Pap smear.(5)
338 Nonetheless, it remains a cornerstone of cervical cancer prevention strategies. There is a pressing
339 need to improve its accessibility and integration into healthcare systems, especially for populations
340 at higher risk, such as HIV-seropositive women.

341 This study is not without limitation. The cross-sectional nature of this research did indeed
342 restrict the ability to establish causal relationships between high-risk HPV infection and cervical
343 cytological abnormalities. The reliance on self-reported data for certain demographic and
344 behavioral factors might also affect the accuracy of the information collected. This study was
345 conducted in specific region in Indonesia, that was bali, which may not account for regional
346 variations in HPV prevalence in Indonesia; nonetheless, this study proved that in Bali, a different
347 type of HPV was found to be more prevalent than the usual high-risk HPV found in other areas in
348 the world.

349

350 **Conclusions**

351 Our research found HR-HPV 18 as a significant risk factor for cervical cytological
352 abnormalities and potentially, cervical cancer in women living with HIV, supporting the indicative
353 measure for a routine pap-smear screening in this specified population. Along with the pap smear,
354 vaccination for HR-HPV 18 also becomes urgently important to be readily supplied in Indonesia.

355

356 **Competing interests**

357 No competing interests is declared in the writing of this manuscript.

358

359 **Authors' contributions**

360 We would like to thank our outstanding team who have helped us in completing this research;
361 Study committee: TREAT Asia: Annette Sohn, Thida Chanyachukul; Kirby Institute: Kathy
362 Petoumenos; Molecular Biology Laboratory Udayana University: Ida Bagus Nyoman Putra Dwija;
363 Pathology Anatomy Faculty of Medicine Udayana University: Nyoman Winarti; Prof Ngoerah
364 Hospital VCT Clinic: Komang Sutarni, Made Ratni; WM Medika Clinic - Kerti Praja Foundation
365 Denpasar: Ni Made Vidia Pratiwi, Ni Kadek Ayu Astuti; Social workers accompanying PLWHA
366 at VCT Prof Ngoerah Denpasar: ketut Rediten, Dedi Junaedi, Afrina Dili Astuti.

367

368 **Funding**

369 This study is supported by the U.S. National Institutes of Health's National Institute of Allergy
370 and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and
371 Human Development, the National Cancer Institute, the National Institute of Mental Health, the
372 National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National

373 Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and
374 Kidney Diseases, and the Fogarty International Center, as part of the International Epidemiology
375 Databases to Evaluate AIDS (IeDEA; U01AI069907). The content of this publication is solely the
376 responsibility of the authors and does not necessarily represent the official views of any of the
377 governments or institutions mentioned above.

378

379 **References**

380

- 381 1. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates
382 of the global burden of cervical cancer associated with HIV. *Lancet Glob Health*. 2021 Feb
383 1;9(2):e161–9.
- 384 2. Jin ZY, Liu X, Ding YY, Zhang ZF, He N. Cancer risk factors among people living with
385 HIV/AIDS in China: A systematic review and meta-analysis. *Sci Rep*. 2017 Dec 1;7(1).
- 386 3. Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, et al. Cervical cancer
387 risk in women living with HIV across four continents: A multicohort study. *Int J Cancer*.
388 2020 Feb 1;146(3):601–9.
- 389 4. WHO. Tackling NCDs: ‘best buys’ and other recommended interventions for the prevention
390 and control of noncommunicable diseases; updated (2017) appendix 3 of the Global Action
391 Plan for prevention and control of noncommunicable diseases 2013–2020. 2017;
- 392 5. Robbers GML, Bennett LR, Spagnoletti BRM, Wilopo SA. Facilitators and barriers for the
393 delivery and uptake of cervical cancer screening in Indonesia: a scoping review. Vol. 14,
394 *Global Health Action*. Taylor and Francis Ltd.; 2021.
- 395 6. Kementean Kesehatan RI Indonesia. Kementerian Kesehatan RI. Profil Kesehatan
396 Indonesia 2016 Kementerian Kesehatan Indonesia [Internet]. 2017.
- 397 7. Ogu CO, Achukwu PU, Nkwo PO. Prevalence and risk factors of Cervical Cytological
398 abnormalities among human immunodeficiency virus sero-positive females on highly active
399 antiretroviral therapy in Enugu, Southeastern, Nigeria. *Asian Pacific Journal of Cancer*
400 *Prevention*. 2019;20(10):2987–94.
- 401 8. WHO. WHO guideline for screening and treatment of cervical pre-cancer lesions for
402 cervical cancer prevention. 2021.
- 403 9. Verrier F, Le Coeur S, Delory T. Cervical human papillomavirus infection (Hpv) and high
404 oncogenic risk genotypes among women living with hiv in asia: A meta-analysis. Vol. 10,
405 *Journal of Clinical Medicine*. MDPI; 2021.
- 406 10. Menon S, Wusiman A, Boily MC, Kariisa M, Mabeya H, Luchters S, et al. Epidemiology
407 of HPV genotypes among HIV positive women in Kenya: A systematic review and meta-
408 analysis. *PLoS One*. 2016 Oct 1;11(10).
- 409 11. Freitas BC, Suehiro TT, Consolaro MEL, Silva VRS. HPV infection and cervical
410 abnormalities in HIV positive women in different regions of Brazil, a middle-income
411 country. *Asian Pacific Journal of Cancer Prevention*. 2016;16(18):8085–91.

- 412 12. Mapanga W, Girdler-Brown B, Feresu SA, Chipato T, Singh E. Prevention of cervical
413 cancer in HIV-seropositive women from developing countries through cervical cancer
414 screening: A systematic review. Vol. 7, Systematic Reviews. BioMed Central Ltd.; 2018.
- 415 13. Asangbeh-Kerman SL, Davidović M, Taghavi K, Kachingwe J, Rammipi KM, Muzingwani
416 L, et al. Cervical cancer prevention in countries with the highest HIV prevalence: a review
417 of policies. BMC Public Health. 2022 Dec 1;22(1).
- 418